When Canada legalized marijuana, the Cannabis Act made it obvious: in order for a business to check their products on people in the growth phase —that is, have subjects sample them before discharging them to customers —it has to be allowed an extra category of license. Just with a study permit, a record which needs a different (and somewhat onerous) program can a cannabis-containing product be lawfully tested on people.
That may not seem like that big a deal until you consider how badly the first tide of cannabis products rolled out in Canada: despite being endorsed by billions of dollars, several big accredited manufacturers found themselves plagued by scandals, principal among them merchandise quality problems. In 2018, customers complained of sterile, underweight, and sterile cannabis, and subsequently, once the next wave of regulations allowed edibles and vape goods in 2019, infused drinks had problems associated with canning and effectiveness. The record went on.
Since that time, the consensus is that grade has begun to increase, and although not all businesses are public regarding their usage of their study permit for individual trials, a trend is emerging. Smaller firms with more tactical plays and not as bloated worker rosters are starting to carve out markets of their own thanks to some other kind of advantage: IP.
– Read the whole post at Forbes.